New drug targets Parkinson's protein in first human test
NCT ID NCT07216066
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called ALN-SNCA in 46 people with early Parkinson's disease. The drug is designed to lower levels of a harmful protein, alpha-synuclein, in the brain. The main goal is to check if the drug is safe and tolerable, and to see how it moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALN-SNCA
What this could lead to
If it works, this could point toward a treatment that slows or stops Parkinson's disease progression by reducing harmful protein buildup in the brain.
What could go wrong
This is a very early, small Phase 1 study focused on safety, not effectiveness. The drug may not lower the protein enough or could cause side effects, and many early-stage drugs fail to advance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSONS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Human Drug Research
RECRUITINGLeiden, South Holland, 2333 CL, Netherlands
-
Montreal Neurological Institute and Hospital
RECRUITINGMontreal, Quebec, H3A 2B4, Canada